Cargando…

Erratum: Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829702/ https://www.ncbi.nlm.nih.gov/pubmed/35153803 http://dx.doi.org/10.3389/fphar.2022.849039

Ejemplares similares

Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Preparation and evaluation of mucoadhesive cefdinir microcapsules
por: Veerareddy, Prabhakar Reddy, et al.
Publicado: (2011)

In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates
por: Li, Fu, et al.
Publicado: (2018)

In vitro activity of new combinations of β-lactam and β-lactamase inhibitors against the Mycobacterium tuberculosis complex
por: Economou Lundeberg, Elin, et al.
Publicado: (2023)

Design and development of cefdinir niosomes for oral delivery
por: Bansal, Saurabh, et al.
Publicado: (2013)

Amoxicillin/cefdinir: Status epilepticus: case report
Publicado: (2020)

Electrochemistry and determination of cefdinir by voltammetric and computational approaches
por: Taşdemir, İbrahim Hüdai
Publicado: (2014)

New Conformations of Acylation Adducts of Inhibitors of β-Lactamase from Mycobacterium tuberculosis
por: Tassoni, Raffaella, et al.
Publicado: (2019)

The G132S Mutation Enhances the Resistance of Mycobacterium tuberculosis β-Lactamase against Sulbactam
por: van Alen, Ilona, et al.
Publicado: (2021)

Efficacy of β-lactam/β-lactamase inhibitor combination is linked to WhiB4-mediated changes in redox physiology of Mycobacterium tuberculosis
por: Mishra, Saurabh, et al.
Publicado: (2017)

Cefdinir associated bloody stool in Riyadh infant: A case report
por: Bahkali, Haytham Ali, et al.
Publicado: (2020)

Development of a spectrophotometric analytical approach for the measurement of cefdinir in various pharmaceuticals
por: Mahmood, Ali Khalil, et al.
Publicado: (2023)

Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor
por: Dowell, James A., et al.
Publicado: (2021)

Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects
por: Rizk, Matthew L., et al.
Publicado: (2018)

Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects
por: Lickliter, Jason D., et al.
Publicado: (2020)

Mycobacterium tuberculosis β-lactamase variant reduces sensitivity to ampicillin/avibactam in a zebrafish-Mycobacterium marinum model of tuberculosis
por: van Alen, Ilona, et al.
Publicado: (2023)

Penicillin Binding Proteins and β-Lactamases of Mycobacterium tuberculosis: Reexamination of the Historical Paradigm
por: Kumar, Gaurav, et al.
Publicado: (2022)

Alginate-Capped Silver Nanoparticles as a Potent Anti-mycobacterial Agent Against Mycobacterium tuberculosis
por: Chen, Cheng-Cheung, et al.
Publicado: (2021)

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants
por: Rhee, Elizabeth G., et al.
Publicado: (2018)

Long-term economic evaluation of the recombinant Mycobacterium tuberculosis fusion protein (EC) test for the diagnosis of Mycobacterium tuberculosis infection
por: Diao, Sha, et al.
Publicado: (2023)

In vitro Activity of Repurposed Nitroxoline Against Clinically Isolated Mycobacteria Including Multidrug-Resistant Mycobacterium tuberculosis
por: Hoffmann, Ada Marie, et al.
Publicado: (2022)

Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum
por: Sarathy, Jansy P., et al.
Publicado: (2018)

Influence of Organic Matter on the Sorption of Cefdinir, Memantine and Praziquantel on Different Soil and Sediment Samples
por: Mutavdžić Pavlović, Dragana, et al.
Publicado: (2022)

281. Cefdinir Prescribing Increased in Low-Income Children in Kentucky From 2012 to 2016
por: Smith, Michael, et al.
Publicado: (2018)

Cefdinir Solid Dispersion Composed of Hydrophilic Polymers with Enhanced Solubility, Dissolution, and Bioavailability in Rats
por: Cho, Hyun-Jong, et al.
Publicado: (2017)

Phosphate Promotes the Recovery of Mycobacterium tuberculosis β-Lactamase from Clavulanic Acid Inhibition
por: Elings, Wouter, et al.
Publicado: (2017)

The in vitro effect of new combinations of carbapenem–β-lactamase inhibitors for Mycobacterium abscessus
por: Fröberg, Gabrielle, et al.
Publicado: (2023)

Discovery of Quercetin and Its Analogs as Potent OXA-48 Beta-Lactamase Inhibitors
por: Zhang, Yuejuan, et al.
Publicado: (2022)

Erratum: Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors
por: Frontiers Production Office,
Publicado: (2023)

Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis
por: Piton, Jérémie, et al.
Publicado: (2018)

β-Lactamases and β-Lactamase Inhibitors in the 21st Century
por: Tooke, Catherine L., et al.
Publicado: (2019)

Identification of substandard drug products using electronic tongue: cefdinir suspension as a pilot example
por: Abu-Khalaf, Nawaf, et al.
Publicado: (2019)

Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations
por: Sarathy, Jansy, et al.
Publicado: (2019)

Comparison of Rifamycins for Efficacy Against Mycobacterium avium Complex and Resistance Emergence in the Hollow Fiber Model System
por: Boorgula, Gunavanthi D., et al.
Publicado: (2021)

Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

A Trisubstituted Benzimidazole Cell Division Inhibitor with Efficacy against Mycobacterium tuberculosis
por: Knudson, Susan E., et al.
Publicado: (2014)

Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against Mycobacterium tuberculosis
por: Xu, Yitian, et al.
Publicado: (2018)

Erratum: Advances in RIPK1 kinase inhibitors
Publicado: (2023)

Identification of Novel Chemical Scaffolds that Inhibit the Growth of Mycobacterium tuberculosis in Macrophages
por: Ahmed, Sara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iqmaqff36tkitchs86nftdkai2